Raul Chertkoff

1.3k citations

54 papers · 655 indexed · h-index 16

Co-authors: Ari Zimran Einat Brill‐Almon Sari Alon Pilar Giraldo Gregory M. Pastores Мilan Petakov Deborah Elstein Einat Almon
Topics: Lysosomal Storage Disorders Research (45 papers)Carbohydrate Chemistry and Synthesis (26 papers)Trypanosoma species research and implications (15 papers)
Cited by: Biotechnology Physiology Cell Biology
Journals: Blood Gastroenterology PLoS ONE
Partner nations: Israel United States United Kingdom

In The Last Decade

Raul Chertkoff

51 papers receiving 635 citations

Peers

Countries citing papers authored by Raul Chertkoff

Since Specialization

Citations

This map shows the geographic impact of Raul Chertkoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raul Chertkoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raul Chertkoff more than expected).

Fields of papers citing papers by Raul Chertkoff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raul Chertkoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raul Chertkoff. The network helps show where Raul Chertkoff may publish in the future.

Co-authorship network of co-authors of Raul Chertkoff

This figure shows the co-authorship network connecting the top 25 collaborators of Raul Chertkoff. A scholar is included among the top collaborators of Raul Chertkoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raul Chertkoff. Raul Chertkoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase III, open‐label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies 2024 ·Journal of Inherited Metabolic Disease ·Myrl Holida,Aleš Linhart,Antonio Pisani,Nicola Longo,François Eyskens,Özlem Göker-Alpan,Eric Wallace,Patrick Deegan,Camilla Tøndel,Ulla Feldt‐Rasmussen,Derralynn Hughes,(unknown),(unknown),Einat Almon,Sari Alon,Raul Chertkoff,David G. Warnock,Stephen Waldek,William R. Wilcox,John Bernat	6
2	Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease 2023 ·Genetics in Medicine ·Derralynn Hughes,Derlis Gonzalez,Gustavo Maegawa,John Bernat,Myrl Holida,Pilar Giraldo,Mohamed G. Atta,Raul Chertkoff,Sari Alon,Einat Almon,Rossana Rocco,Özlem Göker-Alpan	20
3	Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study 2023 ·Orphanet Journal of Rare Diseases ·Aleš Linhart,Gabriela Dostálová,Kathy Nicholls,Michael L. West,Camilla Tøndel,Ana Jovanović,Pilar Giraldo,Bojan Vujkovac,Tarekegn Geberhiwot,Einat Brill‐Almon,Sari Alon,Raul Chertkoff,(unknown),Derralynn Hughes	24
4	Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in patients with Fabry disease: Two-year interim results from the ongoing phase 3 BRIGHT51 open-label extension study 2023 ·Molecular Genetics and Metabolism ·John Bernat,Myrl Holida,Nicola Longo,Özlem Göker-Alpan,Eric Wallace,Patrick Deegan,Camilla Tøndel,François Eyskens,Ulla Feldt‐Rasmussen,Derralynn Hughes,Antonio Pisani,Rossana Rocco,Einat Almon,Sari Alon,Raul Chertkoff,David G. Warnock,Stephen Waldek,William R. Wilcox	2
5	Open-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy 2020 ·Blood Cells Molecules and Diseases ·David J. Kuter,Michael P. Wajnrajch,(unknown),Rong Wang,Raul Chertkoff,Ari Zimran	4
6	Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems—The taliglucerase alfa story 2017 ·PLoS ONE ·Bonita Rup,Sari Alon,(unknown),Einat Almon,Raul Chertkoff,Yoram Tekoah,Pauline M. Rudd	39
7	An oral administration of a recombinant anti-TNF fusion protein is biologically active in the gut promoting regulatory T cells: Results of a phase I clinical trial using a novel oral anti-TNF alpha-based therapy 2017 ·Journal of Immunological Methods ·Einat Almon,Tawfik Khoury,(unknown),Svetlana Gingis‐Velitski,Sari Alon,Raul Chertkoff,(unknown),Yoseph Shaaltiel,Yaron Ilan	20
8	Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase 2016 ·Blood Cells Molecules and Diseases ·Ari Zimran,(unknown),Aya Abrahamov,Peter A. Cooper,(unknown),Pilar Giraldo,Мilan Petakov,Ee Shien Tan,Raul Chertkoff	27
9	Long-term efficacy and safety results of taliglucerase alfa through 5 years in adult treatment-naïve patients with Gaucher disease 2016 ·Blood Cells Molecules and Diseases ·Ari Zimran,(unknown),Pilar Giraldo,Hanna Rosenbaum,Fiorina Giona,Мilan Petakov,(unknown),Sergio Solorio,Peter A. Cooper,(unknown),Sari Alon,Raul Chertkoff	22
10	Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease 2015 ·PLoS ONE ·Richat Abbas,Glen Park,Bharat Damle,Raul Chertkoff,Sari Alon	9
11	Long-term safety and efficacy of taliglucerase alfa in pediatric patients with Gaucher disease who were treatment-naïve previously treated with immiglucerase 2015 ·Molecular Genetics and Metabolism ·Ari Zimran,(unknown),Aya Abrahamov,Peter A. Cooper,(unknown),Alona Paz,Einat Brill‐Almon,Raul Chertkoff	1
12	Preclinical and first-in-human evaluation of PRX-105, a PEGylated, plant-derived, recombinant human acetylcholinesterase-R 2015 ·Toxicology and Applied Pharmacology ·Jacob Atsmon,Einat Brill‐Almon,(unknown),Raul Chertkoff,Sari Alon,(unknown),(unknown),(unknown),Daniel Bartfeld,Avidor Shulman,(unknown),Tehila Ben-Moshe,(unknown),Hermona Soreq,Yoseph Shaaltiel	16
13	A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase 2014 ·Gregory M. Pastores,Мilan Petakov,Pilar Giraldo,Hanna Rosenbaum,Jeff Szer,Patrick Deegan,Dominick Amato,Eugen Mengel,Ee Shien Tan,Raul Chertkoff,Einat Brill‐Almon,Ari Zimran	1
14	A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase 2014 ·Blood Cells Molecules and Diseases ·Gregory M. Pastores,Мilan Petakov,Pilar Giraldo,Hanna Rosenbaum,Jeff Szer,Patrick Deegan,Dominick Amato,Eugen Mengel,Ee Shien Tan,Raul Chertkoff,Einat Brill‐Almon,Ari Zimran	46
15	Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease 2014 ·Blood Cells Molecules and Diseases ·Ari Zimran,(unknown),Aya Abrahamov,Deborah Elstein,Alona Paz,Einat Brill‐Almon,Raul Chertkoff	25
16	Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease 2012 ·Blood Cells Molecules and Diseases ·Laura van Dussen,Ari Zimran,Erik M. Akkerman,Johannes M. F. G. Aerts,Мilan Petakov,Deborah Elstein,Hanna Rosenbaum,David Aviezer,Einat Brill‐Almon,Raul Chertkoff,Mario Maas,Carla E. M. Hollak	31
17	Improving the accuracy of MRI spleen and liver volume measurements: A phase III Gaucher disease clinical trial setting as a model 2010 ·Blood Cells Molecules and Diseases ·Luc Bracoud,(unknown),Einat Brill‐Almon,Raul Chertkoff	15
18	6. Novel enzyme replacement therapy for Gaucher disease: On-going phase III clinical trial with recombinant human glucocerebrosidase expressed in plant cells 2008 ·Molecular Genetics and Metabolism ·David Aviezer,(unknown),(unknown),Gad Galili,Raul Chertkoff,Sharon Hashmueli,(unknown),Ari Zimran	20
19	National health budgets for expensive orphan drugs: Gaucher disease in Israel as a model 2006 ·Blood Cells Molecules and Diseases ·(unknown),Deborah Elstein,Avi Israeli,Raul Chertkoff,Ari Zimran	11
20	The role of the iminosugar N‐butyldeoxynojirimycin (miglustat) in the management of type I (non‐neuronopathic) Gaucher disease: A position statement 2003 ·Journal of Inherited Metabolic Disease ·Timothy M. Cox,Johannes M. F. G. Aerts,Generoso Andria,Michael Beck,Nadia Belmatoug,Bruno Bembi,Raul Chertkoff,Stephan vom Dahl,Deborah Elstein,Anders Erikson,M Giralt,René Heitner,Carla E. M. Hollak,(unknown),Susan E. Lewis,Atul Mehta,Gregory M. Pastores,A. Rolfs,Clara Sá-Miranda,Ari Zimran	187

About Raul Chertkoff

Raul Chertkoff is a scholar working on Physiology, Biotechnology and Organic Chemistry, having authored 54 papers that have together received 655 indexed citations. Recurring topics across this work include Lysosomal Storage Disorders Research (45 papers), Carbohydrate Chemistry and Synthesis (26 papers) and Trypanosoma species research and implications (15 papers). The work is most often cited by research in Biotechnology (147 citations), Physiology (421 citations) and Cell Biology (166 citations). Raul Chertkoff has collaborated with scholars based in Israel, United States and United Kingdom. Frequent co-authors include Ari Zimran, Einat Brill‐Almon, Sari Alon, Pilar Giraldo, Gregory M. Pastores, Мilan Petakov, Deborah Elstein, Einat Almon, Carla E. M. Hollak and Johannes M. F. G. Aerts. Their work appears in journals such as Blood, Gastroenterology and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact